Charles River Laboratories CRL DSA — Operating Income (Loss)
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Charles River Laboratories in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The official record: Charles River Laboratories’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Charles River Laboratories's dsa — operating income (loss).
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Charles River Laboratories's DSA — operating income (loss)?
- Charles River Laboratories (CRL) reported DSA — operating income (loss) of $103.88M in Q1 2026.
- How has Charles River Laboratories's DSA — operating income (loss) changed year-over-year?
- Charles River Laboratories's DSA — operating income (loss) increased by 10.6% year-over-year, from $93.95M to $103.88M.
- What is the long-term trend for Charles River Laboratories's DSA — operating income (loss)?
- Over 2 years (2023 to 2025), Charles River Laboratories's DSA — operating income (loss) has grown at a -16.3% compound annual growth rate (CAGR), from $606.08M to $424.56M.
- What does DSA — operating income (loss) mean?
- The profit or loss generated by the segment's core business activities before interest and taxes.
- How do you interpret DSA — operating income (loss)?
- Higher operating income demonstrates strong operational leverage and effective cost control within the segment.
- How does DSA — operating income (loss) compare across companies?
- Standard segment-level profitability metric used by all public companies.